Abstract: Provided are methods of preparing organoids and compositions for use in such methods. In some embodiments, a method of depositing a plurality of the cells into a reservoir are provided, the method comprising depositing a gelatin composition into a reservoir; adding a composition comprising a plurality of cells into the gelatin composition, wherein the composition is added into the gelatin composition at a position below the surface of the gelatin composition and at least a portion of the composition and/or plurality of cells are suspended in the gelatin composition; curing at least a portion of the composition comprising the plurality of cells in the gelatin composition; and removing at least a portion of the gelatin composition in the reservoir, thereby depositing the plurality of cells in the reservoir.

Abstract: Provided herein are methods of producing TILs via (i) pre-REP stimulation with a combination of interferon gamma (IFN?) and an anti-PD-1 antibody, with or without a CD40 agonist, and with or without an anti-CTLA-4 antibody (ii) various concentrations of IL-15 and IL-21, with or without low-concentration IL-2, with or without an AKT inhibitor (AKTi) during REP expansion and/or pre-REP expansion, (iii) low-concentration IL-2 and an AKTi during REP expansion and/or pre-REP expansion, (iv) the combination of (i) and (ii), or (v) the combination of (i) and (iii).

Abstract: The present invention provides a method for screening for platelet production promoters, the method including a step for selecting a candidate substance that significantly increases expression of TUBB1 as a platelet production promoter.

Abstract: A method for determining the mated status of female fruit flies, focusing on determining the presence of spermatozoa in a sample fly's ventral receptacle (VR). The ventral receptacle is the organ where eggs become fertilized. The VR is the first and last organ in a mated female fly to contain spermatozoa. The VR is thus the most accurate organ for determining whether a female fruit fly has recently mated. The method is a squash method. The fly's ventral receptacle is isolated, and then squeezed so as to cause spermatozoa stored in the ventral receptacle to be released into the lumen of the VR. This permits use of a microscope to determine the presence or absence of spermatozoa in the female fruit fly, and thus the mated status of the female fruit fly.

Abstract: Provided herein are methods for the production of activated CD26high T cells by co-stimulation with inducible coactivator (ICOS). Further provided are methods for treatment of cancer by administration of the of activated CD26high T cells as an adoptive T cell therapy.

Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.

Abstract: Disclosed is a composition for selective enrichment of progressively motile non-fragmented/intact DNA sperms during swim-up of semen sample comprising combination of electrolytes, a mix of excipients, polyyvinylpyrrolidone, recombinant human serum albumin or bovine serum albumin. A method of selective enrichment of DNA-intact sperms using the compositions of the present invention is also disclosed. The DNA fragmentation index of the swim-up sperms are less than the DNA fragmentation index of the neat samples. The media compositions of the present invention are applicable for enrichment of non-fragmented/intact DNA sperms for therapeutic purposes in the field of assisted reproductive technologies.

Abstract: A liquid for cryopreserving a cell and a liquid for administration of a mammalian cell capable of cryopreserving a mammalian cell and effectively suppressing cell death after thawing, and a method for cryopreserving a mammalian cell using the cell cryopreservation liquid. The liquid is an isotonic solution that includes 2.0 to 6.0% (w/v) of trehalose or a derivative thereof, or a salt of the trehalose or the derivative, 4.0 to 7.0% (w/v) of dextran or a derivative thereof, or a salt of the dextran or the derivative, and DMSO or glycerin.

Abstract: The present invention provides a fluidic chip for cell culture use which can prevent a decrease in the activity of cultured cells in a preparation stage, and which makes it possible to observe a cultured cell tissue while detaching the cultured cell tissue from the fluidic chip.

Abstract: Disclosed are methods of preparing hematopoietic stem cells and progenitor cells (HSPCs) for transplant into a subject and to methods of using the treated cells. More particularly, methods of the invention comprise treating HSPCs ex vivo with an effective amount of a GABBR1 agonist and administering the treated HSPCs to the subject.

Abstract: This invention relates to variants of Cas12a nucleases having altered protospacer adjacent motif recognition specificity. The invention further relates to methods of making CRISPR-CAS nuclease variants and methods of modifying nucleic acids using the variants.

Abstract: The present invention relates to components, systems, and methods transcriptional modification (e.g., transcriptional activation) or methods of identifying transcriptional effectors based on Cas9-transcription effector fusion protein and gRNA sequence targeting.

Abstract: Disclosed herein are methods for generating mature cardiomyocytes and compositions including mature cardiomyocytes. Also disclosed herein are methods for enhancing maturation of quiescent cardiomyocytes and compositions including mature quiescent cardiomyocytes.

Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: The present invention refers to a process for reducing the amount of undesired components in an oil composition, particularly in an oil composition comprising omega-3 polyunsaturated fatty acids. The process of the present invention provides efficient removal of undesired water-soluble (hydrophilic) components and undesired fat-soluble (lipophilic) components from an oil composition in order to obtain a purified concentrate, e.g. a highly purified concentrate enriched in omega-3 polyunsaturated fatty acids.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.